Hansa to restructure

Hansa Biopharma AB, has announced that it plans to restructure the organization to optimize resource allocation and improve operational efficiency. The planned restructuring would result in an approximately 20% reduction in the current workforce and will result in projected annual savings of 40-50 MSEK in annual savings. The restructuring is subject to negotiation with relevant trade unions. Renée Aguiar-Lucander, CEO, Hansa Biopharma said: “This planned restructuring is a strategic decision to optimize resources and improve operational efficiency at a critical time for the organization. We anticipate this will lead to cost savings as well as increased efficiency, transparency and accountability throughout the organization. We are confident that these changes are necessary and will position us to more effectively deliver value to shareholders and patients.” As part of the restructuring, Hansa will notify the Swedish Public Employment Service (Sw. Arbetsförmedlingen) and seek consultations with the trade unions regarding the reorganisation. Decisions regarding employee reductions will take place after the change consultations have been concluded according to local regulations.